Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Davis, S. T., Benson, B. G., Bramson, H. N., Chapman, D. E., Dickerson, S. H., Dold, K. M., Eberwein, D. J., Edelstein, M., Frye, S. V., Gampe, R. T., et al. (2001) · Science · doi:10.1126/science.291.5501.134 · Cited by 166
RetractedThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids
Holland, B. T., Blanford, C. F., & Stein, A. (1998) · Science · doi:10.1126/science.281.5376.538 · Cited by 1,484
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Research works printed but not linked: 46
- Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
- Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
- Fry D. W., 2000, Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs, 2, 59
- Gray N., 1999, Curr. Med. Chem., 6, 875
- Fry D. W., 2001, J. Biol. Chem., 276, 16623
- Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
- Chang Y.-T., 1999, Chem. Biol., 6, 375
- Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
- Zaharevitz D. W., 1999, Cancer Res., 59, 2569
- Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
- Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
- Kim K. S., 2002, J. Med. Chem., 45, 3927
- Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
- Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
- Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
- Seong Y.-S., 2003, Cancer Res., 63, 7391
- Kim K. S., 2000, J. Med Chem., 43, 4134
- Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
- Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
- Yue E. W., 2002, J. Med. Chem., 45, 5248
- Lane M. E., 2001, Cancer Res., 61, 6177
- Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
- Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
- Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
- Honma T., 2001, J. Med. Chem., 44, 4627
- Honma T., 2001, J. Med. Chem., 44, 4640
- Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
- Zhu G., 2003, J. Med. Chem., 46, 2030
- Bartek J., 2003, Biochem. J., 371, 204
- Bartkova J., 1997, Prog. Cell Cycle Res., 3, 220
- Hall M., 1996, Adv. Cancer Res., 68, 108
- Misra R. N., 2004, Chem
- Kelland L. R., 2000, Exp. Opin. Invest. Drugs, 9, 2911
- Chao S.-H., 2001, J. Biol. Chem., 276, 31799
- Chao S.-H., 2000, J. Biol. Chem., 275, 28348
- Tetsu O., 2003, Cancer Cell, 2, 245
- Fry D. W., 2004, Mol. Cancer Ther., 3, 1437
- Meyerson M., 1994, Mol. Cell Biol., 14, 2086
- Fry D. W., 1994, Anticancer Drug Des., 9, 351
- Fry D. W., 1997, Biochem. Pharmacol., 54, 887
Cited by
Items 201–300 of 555
Huang, Z. L., Zhao, B., Qin, Z., Li, Y., Wang, T., Zhou, W., Zheng, J., Yang, S., Shi, Y., Fan, Y. L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.044 · Cited by 40
Hou, Y., Zhu, L., Li, Z., Shen, Q., Xu, Q., Li, W., Liu, Y., & Gong, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.009 · Cited by 39
Li, Y., Zhao, J., Gutgesell, L. M., Shen, Z., Ratia, K. M., Dye, K., Dubrovskyi, O., Zhao, H., Huang, F., Tonetti, D. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00456 · Cited by 41
Recent advances in multitarget-directed ligands via in silico drug discovery
Krishnaiah, M., Yada, B., Kumari, S., McHale, C. C., Pal, D., & Durden, D. L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103904 · Cited by 44
Synthesis and anticancer activity of some novel fused pyridine ring system
Elansary, A. K., Moneer, A. A., Kadry, H. H., & Gedawy, E. M. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-1107-6 · Cited by 37
Masuda, N., Nishimura, R., Takahashi, M., Inoue, K., Ohno, S., Iwata, H., Mori, Y., Hashigaki, S., Muramatsu, Y., Nagasawa, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13507 · Cited by 37
“Median average duration of cycle delay, d (range) 7 (5-47) 7 (5-47)”
BackgroundThibault, S., Hu, W., Hirakawa, B. P., Kalabat, D. Y., Franks, T., Sung, T., Khoh‐Reiter, S., Lu, S., Finkelstein, M. B., Jessen, B. A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0734 · Cited by 38
“Inhibition of CDK4/6 prevents cell proliferation leading to tumor growth arrest (7-11).”
BackgroundClinical Implications of Androgen-Positive Triple-Negative Breast Cancer
Brumec, M., Sobočan, M., Takač, I., & Arko, D. (2021) · Cancers · doi:10.3390/cancers13071642 · Cited by 37
“In addition, an important therapeutic method for LAR subgroup of TNBC [99,100], the CDK 4/6 inhibition (palbociclib) is clinically emerging in the last years.”
MethodUSP7 limits CDK1 activity throughout the cell cycle
Galarreta, A., Valledor, P., Ubieto‐Capella, P., Lafarga, V., Zarzuela, E., Muñoz, J., Malumbres, M., Lecona, E., & Fernández-Capetillo, Ó. (2021) · The EMBO Journal · doi:10.15252/embj.201899692 · Cited by 39
“In contrast, palbociclib, a dual CDK4/CDK6 inhibitor (Toogood et al, 2005), did not have any impact on the increase in H3S10P and MPM-2 triggered by USP7i (Fig EV2A).”
El‐Nassan, H. B. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.055 · Cited by 37
Knudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 39
Dall’Acqua, A., Bartoletti, M., Masoudi-Khoram, N., Sorio, R., Puglisi, F., Belletti, B., & Baldassarre, G. (2021) · Cancers · doi:10.3390/cancers13123035 · Cited by 41
“Then, experiments in cells and mouse models of cancer confirmed that PD0332991 displayed very promising antitumor activities [13,43,44], but it took many years until its therapeutic value became really appreciated, as described by Garber in 2014 [45].”
BackgroundEffect of food on the bioavailability of palbociclib
Ruiz-García, A., Plotka, A., O’Gorman, M. T., & Wang, D. D. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3246-4 · Cited by 39
“Palbociclib (IBRANCE®) is an orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 [1, 2] that block cell-cycle progression from G1 to S phases, thereby preventing DNA synthesis and cellular proliferation [3–5].”
BackgroundWang, Y., Chen, X., Yan, Y., Zhu, X., Liu, M., & Liu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02121 · Cited by 36
Romano, G. (2013) · ISRN Oncology · doi:10.1155/2013/305371 · Cited by 47
“The second generation of CDK inhibitors includes PD-0332991, P276-00, AT-7519, and RGB-286638 (Table 3) [13, 26–28, 135–144].”
Mintoo, M. J., Khan, S. U., Wani, A., Malik, S., Bhurta, D., Bharate, S. B., Malik, F. A., & Mondhe, D. M. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23332 · Cited by 34
Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity
Tuomela, K., Mukherjee, D., Ambrose, A. R., Harikrishnan, A., Mole, H., Hurlstone, A. F. L., Önfelt, B., Honeychurch, J., & Davis, D. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111900119 · Cited by 36
“Next, Colo829 cells were treated with palbociclib, a cyclindependent kinase 4/6 inhibitor that arrests cells at G0/1 (25) (SI Appendix, Fig.”
Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors
Liu, M., Zhou, G., Su, W., Gu, Y., Gao, M., Wang, K., Huo, R., Li, Y., Zhou, Z., Chen, K., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00490 · Cited by 33
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
Schröder, L. B. W., & McDonald, K. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00259 · Cited by 41
“PD0332991 is a highly specific CDK4/6 inhibitor (16) developed by Pfizer for cancer treatment (17).”
BackgroundRole of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
Giannone, G., Tuninetti, V., Ghisoni, E., Genta, S., Scotto, G., Mittica, G., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092353 · Cited by 35
“The chemical name of palbociclib is 6-acetyl-8-cyclopentyl-5-methyl-2-pyrido[2,3-d]pyrimidin-7(8H)-one [61].”
BackgroundDiverse Targeted Approaches to Battle Multidrug Resistance in Cancer
Shankaraiah, N., Nekkanti, S., Ommi, O., & Soukya, P. S. L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180410110729 · Cited by 32
Aicher, T. D., Huis, C. A. V., Hurd, A. R., Skalitzky, D. J., Taylor, C. B., Beleh, O. M., Glick, G. D., Toogood, P. L., Yang, B., Zheng, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00731 · Cited by 33
Self-citationIngemarsdotter, C. K., Tookman, L. A., Browne, A. K., Pirlo, K. J., Cutts, R. J., Chelela, C., Khurrum, K. F., Leung, E. Y. L., Dowson, S., Webber, L., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.12.007 · Cited by 31
Nomanbhoy, T. K., Sharma, G., Brown, H., Wu, J., Aban, A., Vogeti, S., Alemayehu, S., Sykes, M., Rosenblum, J. S., & Kozarich, J. W. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00629 · Cited by 31
Brighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
Kahán, Z., Gil‐Gil, M., Ruíz‐Borrego, M., Carrasco, E., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Antón, A., Casas, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.004 · Cited by 33
Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches
Grassilli, S., Bertagnolo, V., & Brugnoli, F. (2022) · Diagnostics · doi:10.3390/diagnostics12092139 · Cited by 32
“At variance, Ji and colleagues demonstrate that miR-29b-3p promotes sensitivity of luminal or HER2-positive breast cancer cells to Palbociclib [33], a selective inhibitor of CDK4 and CDK6 kinases, which could prevent progression of the cell cycle from G1 into the S phase in various tumors [89].”
BackgroundSarhan, M. O., El‐Karim, S. S. A., Anwar, M. M., Gouda, R. H., Zaghary, W. A., & Khedr, M. A. (2021) · Molecules · doi:10.3390/molecules26082273 · Cited by 33
Li, C., Qi, L., Bellail, A. C., Hao, C., & Liu, T. (2014) · Oncology Letters · doi:10.3892/ol.2014.1957 · Cited by 33
“PD-0332991 is a highly selective, orally administered and reversible inhibitor of CDK4/6 (11,12).”
Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors
Mahajan, P., Chashoo, G., Gupta, M., Kumar, A., Singh, P. P., & Nargotra, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00293 · Cited by 30
Shimamura, T., Shibata, J., Kurihara, H., Mita, T., Otsuki, S., Sagara, T., Hirai, H., & Iwasawa, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.048 · Cited by 30
Huard, J., Mueller, S., Gilles, E. D., Klingmüller, U., & Klamt, S. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08572.x · Cited by 29
Preclinical and clinical development of palbociclib and future perspectives
de Dueñas, E. M., Gavilá-Gregori, J., Olmos-Antón, S., Santaballa, A., Lluch-Hernández, A., Domínguez, E. E., Rivero-Silva, M., & Llombart‐Cussac, A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1850-3 · Cited by 36
“However, they have limited capacity to inhibit other kinases, including CDK2 (IC50 > 5 μM) [7].”
BackgroundCDK4-6 inhibitors in breast cancer: current status and future development
Choo, J. R.-E., & Lee, S. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541347 · Cited by 32
“Rb phosphorylation leading to G1 arrest and cytostasis [8].”
BackgroundTherapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Chagaleti, B. K., Saravanan, V., & Kathiravan, M. K. (2024) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-024-00577-8 · Cited by 29
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Luca, A. D., Maiello, M. R., D’Alessio, A., Frezzetti, D., Gallo, M., Carotenuto, M., & Normanno, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1514720 · Cited by 28
“The chemical name of palbociclib is 6-acetyl-8-cyclopentyl5-methyl-2-pyrido[2,3-d]pyrimidin-7(8H)-one [10] (Box 1).”
BackgroundDiscovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA
Wang, C., Luo, H., Chen, X., Zhang, Y., Lu, D., Liu, X., Yin, F., Li, S., Kong, L., & Wang, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106683 · Cited by 27
Small-molecule-based targeted therapy in liver cancer
Ming, Y., Gong, Y., Fu, X., Ouyang, X., Peng, Y., & Pu, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.001 · Cited by 32
Gascoyne, D. M., Spearman, H., Lyne, L., Puliyadi, R., Perez‐Alcantara, M., Coulton, L. A., Fisher, S. E., Croucher, P. I., & Banham, A. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128513 · Cited by 28
“Growth arrest of 143B in G1/0, induced by the downstream Cyclin-Dependent Kinase (CDK) inhibitor Palbociclib,[34] (Fig 4C) was not associated with FOXP2 induction or that of p21WAF1/CIP1 (Fig 4D), indicating FOXP2 induction to be an upstream primary event rather than secondary to growth arrest.”
BackgroundParmar, U., Somvanshi, D., Kori, S., Desai, A. A., Dandela, R., Maity, D. K., & Kapdi, A. R. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00845 · Cited by 27
CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Gupta, P., Narayanan, S., & Yang, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00009-2 · Cited by 36
Witkiewicz, A. K., Cox, D. W., Rivadeneira, D. E., Ertel, A., Fortina, P. M., Schwartz, G. F., & Knudsen, E. S. (2013) · Oncogene · doi:10.1038/onc.2013.367 · Cited by 29
Graham, J. S., Hunter, J. H., & Waring, M. J. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c02325 · Cited by 26
New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities
Wang, P., Huang, J., Wang, K., & Gu, Y. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.020 · Cited by 26
2-Aminoquinazoline inhibitors of cyclin-dependent kinases
Bathini, Y., Singh, I., Harvey, P. J., Keller, P. R., Singh, R., Micetich, R. G., Fry, D. W., Dobrusin, E. M., & Toogood, P. L. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.131 · Cited by 31
Self-citationGiovanni, C. D., Novellino, E., Chilin, A., Lavecchia, A., & Marzaro, G. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1234603 · Cited by 26
“In several xenograft models, the drug was efficacious in inducing tumor stasis or regression and was tolerated without significant toxicities at daily doses up to 150 mg/kg for up to 50 days of treatment [93,94].”
BackgroundTaralli, S., Lorusso, M., Scolozzi, V., Masiello, V., Marazzi, F., & Calcagni, M. L. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-01323-8 · Cited by 28
Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold
Shan, H., Ma, X., Yan, G., Luo, M., Zhong, X.-X., Lan, S., Yang, J., Liu, Y., Pu, C., Yu, T., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113432 · Cited by 25
Chen, S., Wang, Q., Liao, X., Ge, H., Huo, G., Zhang, L., Chen, N., Zhai, X., Yuan, H., Wang, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.005 · Cited by 25
The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma
Altenburg, J. D., & Farag, S. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.993753 · Cited by 28
“PD0332991 uses the pyrido[2,3-d]pyrimidin-7-one template that competes with ATP for the ATP-binding pocket [48].”
BackgroundGan, Q., Song, X., Zhang, X., & Zhang, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112032 · Cited by 24
Fluorescent Protein Biosensor for Probing CDK/Cyclin Activity in vitro and in Living Cells
Van, T. N. N., Pellerano, M., Lykaso, S., & Morris, M. C. (2014) · ChemBioChem · doi:10.1002/cbic.201402318 · Cited by 24
Meng, D., Li, L., Brown, A., Desrosiers, J., Duan, S., Hayward, C. M., He, Z., Hu, J., Makowski, T. W., Maloney, M. T., et al. (2021) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2021.100394 · Cited by 25
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
“CDK4 and CDK6, preventing downstream CDK4/6-mediated phosphorylation of Rb [69,70].”
Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25
Jain, P., Flaherty, P. T., Yi, S., Chopra, I., Bleasdell, G., Lipay, J., Ferandin, Y., Meijer, L., & Madura, J. D. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.11.022 · Cited by 23
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor
Deng, Y., Shipps, G. W., Zhao, L., Siddiqui, M. A., Popovici-Müller, J. V., Curran, P. J., Duca, J. S., Hruza, A. W., Fischmann, T. O., Madison, V., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.041 · Cited by 23
Novel Potent Pharmacological Cyclin-Dependent Kinase Inhibitors
Węsierska‐Gądek, J., Chamrád, I., & Kryštof, V. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.110 · Cited by 24
Hu, Z., Li, H., Wang, X., Ullah, K., & Xu, G. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103996 · Cited by 25
Kettle, J. G., & Wilson, D. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.007 · Cited by 24
CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats
Sacaan, A. I., Thibault, S., Hong, M., Kondegowda, N. G., Nichols, T., Li, R., Rosselot, C., Evering, W., Fenutría, R., Vitsky, A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0172 · Cited by 25
“Palbociclib is an orally bioavailable small-molecule reversible inhibitor of CDKs 4 and 6, which phosphorylate the retinoblastoma (Rb) protein (9).”
BackgroundChen, S., Wang, Q., Liao, X., Ge, H., Huo, G., Zhang, L., Chen, N., Zhai, X., Yuan, H., Wang, L., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112239 · Cited by 22
Ketley, A., Wojciechowska, M., Ghidelli, S., Bamborough, P., Ghosh, T. K., López-Morató, M., Sedehizadeh, S., Malik, N. A., Tang, Z., Powalowska, P. K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2415 · Cited by 28
Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer
Ramos, N. N., Baquero‐Buitrago, J., Youss, Z. B., Wadghiri, Y. Z., Reiner, T., Boada, F. E., & Carlucci, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.232603 · Cited by 21
“Specifically, we introduced an 18F prosthetic group (18F-fluorobenzoic acid) on the terminal piperazine (27) and synthesized a novel PET-active functional molecule.”
BackgroundMethodPuyenbroeck, V. V., Claeys, E., Schols, D., Bell, T. W., & Vermeire, K. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.061051 · Cited by 21
“ciclib is a selective inhibitor of cyclin dependent kinase 4 and 6 (Cdk4/D IC50 11 nM) (23) and was used as a control for G1/S arrest.”
MethodNew agents for endocrine resistance in breast cancer
Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017) · The Breast · doi:10.1016/j.breast.2017.04.007 · Cited by 22
Chen, J., Wang, X., Zhang, J. Z. H., & Zhu, T. (2018) · ACS Omega · doi:10.1021/acsomega.8b02354 · Cited by 21
Self-citationEffects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
Sun, Y., Li, Y., Wu, H., Wu, S.-H., Wang, Y., Luo, D., & Liao, D. J. (2011) · Journal of Cancer · doi:10.7150/jca.2.36 · Cited by 27
“Chemical inhibitors of D1 [17-25] or CDK4 [26-36] have been developed as candidates for chemotherapeutic agents [26,37-43].”
BackgroundChekal, B. P., Ewers, J., Guinness, S. M., Ide, N. D., Leeman, K. R., Post, R. J., Rane, A. M., Sutherland, K., Wang, K., Webster, M. E., et al. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00071 · Cited by 23
Dentofacial Parameters Explaining Variability in Retroclination of the Maxillary Central Incisors
Lapatki, B. G., Klatt, A., Schulte‐Mönting, J., & Jonas, I. E. (2007) · Journal of Orofacial Orthopedics / Fortschritte der Kieferorthopädie · doi:10.1007/s00056-007-0637-x · Cited by 27
Yang, B., Quan, Y., Zhao, W., Ji, Y., Yang, X., Li, J., Li, Y., Liu, X., Wang, Y., & Li, Y. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2169282 · Cited by 20
Kumarasamy, V. M., Gao, Z., Zhao, B., Jiang, B., Rubin, S. M., Burgess, K., Witkiewicz, A. K., & Knudsen, E. S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02399-4 · Cited by 20
Sun, Y., Chen, M., Han, Y., Li, W., Ma, X., Shi, Z., Zhou, Y., Xu, L., Yu, L., Wang, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02288 · Cited by 25
Shariati, M., Evans, K. W., Zheng, X., Bristow, C. A., Ng, P. K., Rizvi, Y. Q., Tapia, C., Yang, F., Carugo, A., Heffernan, T. P., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01819-0 · Cited by 20
“Multiple studies have shown that ER-positive cell lines with luminal features were most sensitive to palbociclib—the highly selective inhibitor of CDK4/6—[8, 9] the efficacy is, however, limited by acquired resistance.”
BackgroundRegulation of miR106b cluster through the RB pathway: Mechanism and functional targets
Thangavel, C., Boopathi, E., Ertel, A., Lim, M. K., Addya, S., Fortina, P. M., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.23029 · Cited by 23
“This agent is a potent modulator of RB pathway function that is clinically significant, as it is being evaluated as a therapeutic agent in multiple diseases, including breast cancer.(20,21) As shown, treatment of MCF7 cells with PD-0332991 resulted in significantly altered expression of seven miRNA species (Fig.”
BackgroundTripathy, D., Blum, J. L., Rocque, G. B., Bardia, A., Karuturi, M. S., Cappelleri, J. C., Liu, Y., Zhang, Z., Davis, K. L., & Wang, Y. (2020) · Future Oncology · doi:10.2217/fon-2020-0573 · Cited by 21
Cyclin-dependent kinase 4/6 inhibition in cancer therapy
Johnson, N., & Shapiro, G. I. (2012) · Cell Cycle · doi:10.4161/cc.22390 · Cited by 20
Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation
Deb Roy, A., Gross, E. G., Pillai, G. S., Seetharaman, S., Etienne-Manneville, S., & Inoue, T. (2022) · Journal of Cell Biology · doi:10.1083/jcb.202202100 · Cited by 20
Educate, not kill: treating cancer without triggering its defenses
Škarková, A., Bizzarri, M., Janoštiak, R., Mašek, J., Rösel, D., & Brábek, J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.04.003 · Cited by 21
Fu, W., Sharma, S. S., Ma, L., Chu, B., Bui, M. M., Reed, D. R., & Pledger, W. J. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.101 · Cited by 20
“Hsp90 inhibitors did not induce apoptosis when combined with PD0332991, which selectively targets CDK4 and CDK6 (Supplementary Figure 2c).(26) This finding may be explained by redundant actions of PD0332991 and Hsp90 inhibitors: PD0332991 inactivates CDK4 and CDK6, and Hsp90 inhibitors downregulate CDK4 and CDK6.”
BackgroundEmerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer
Batra, A., & Winquist, E. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1547707 · Cited by 19
“Mechanistically, it has high affinity for the ATP cleft of CDK4/6 at low nanomolar concentrations resulting in reduced RB protein phosphorylation thereby inducing an exclusive G1 arrest and a potent antiproliferative effect [65,66].”
BackgroundSong, X., Gan, Q., Zhang, X., & Zhang, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00540 · Cited by 19
Plett, R., Mellor, P., Kendall, S., Hammond, S. A., Boulet, A., Plaza, K., Vizeacoumar, F. S., Vizeacoumar, F. J., & Anderson, D. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-19621-7 · Cited by 20
Palbociclib: A new hope in the treatment of breast cancer
Palanisamy, R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.168988 · Cited by 19
Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
Zhu, L., Yang, Q., Hu, R., Li, Y., Peng, Y., Liu, H., Ye, M., Zhang, B., Zhang, P., Liu, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09592-0 · Cited by 19
Gas‐Phase Mechanism of O.−/Ni2+‐Mediated Methane Conversion to Formaldehyde
Li, Y., Müller, F., Schöllkopf, W., Asmis, K. R., & Sauer, J. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202202297 · Cited by 18
Mascarenhas, N. M., Bhattacharyya, D., & Ghoshal, N. (2010) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2010.01.008 · Cited by 18
Tetrahydro-3 H -pyrazolo[4,3- a ]phenanthridine-based CDK inhibitor
Opoku‐Temeng, C., Dayal, N., Hernandez, D. E., Naganna, N., & Sintim, H. O. (2018) · Chemical Communications · doi:10.1039/c8cc01154k · Cited by 20
In silico identification of novel CDK4 inhibitors for retinoblastoma
Kumar, M., Srivastava, V., Devi, U., Nackwal, K., Ahmed, M. Z., & Shukla, P. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100743 · Cited by 18
Abemaciclib induces apoptosis in cardiomyocytes by activating the Hippo signaling pathway
Zhou, Y., Li, Y., Shen, J., Li, J., & Li, X. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa066 · Cited by 18
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Guo, Z., Dong, R. W., Wu, Y., Dong, S., & Alahari, S. K. (2025) · Oncogene · doi:10.1038/s41388-025-03378-0 · Cited by 18
“Palbociclib, received FDA approval in 2015, was a highly selective CDK4 and CDK6 inhibitor, with an in vitro enzymatic IC 50 of approximately 11 nM for CDK4 and 15 nM for CDK6, and with >5 uM CDK2 activity [42, 43].”
Prével, C., Kurzawa, L., Van, T. N. N., & Morris, M. C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.003 · Cited by 23
Synthesis of Pyridotriazolopyrimidines as Antitumor Agents
Abdallah, M. A., Gomha, S. M., Morad, M. A., & Elaasser, M. M. (2016) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.2699 · Cited by 17
microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network
Zhou, Y., Frings, O., Branca, R. M., Boekel, J., le Sage, C., Fredlund, E., Agami, R., & Orre, L. M. (2016) · Oncogene · doi:10.1038/onc.2016.242 · Cited by 18
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
Tanaka, T., Terai, Y., Ashihara, K., Fujiwara, S., Tanaka, Y., Sasaki, H., Tsunetoh, S., & Ohmichi, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177019 · Cited by 19
Zuazo-Gaztelu, I., Lawrence, D. A., Oikonomidi, I., Marsters, S. A., Pechuan-Jorge, X., Gaspar, C. J., Kan, D., Segal, E., Clark, K., Beresini, M. H., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003086 · Cited by 16
Saini, S. S., & Klein, M. A. (2011) · PubMed · Cited by 17
Boér, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s77033 · Cited by 19
“In preclinical studies, palbociclib has been shown to target CDK4/6 spe- cifically, with potent inhibition of tumor cell proliferation by G1 arrest, leading to dephosphorylation of pRb, a decrease of E2F-dependent gene expression and potent inhibition of tumor cell proliferation through arrest in G1.”
BackgroundTadesse, S., Zhu, G., Mekonnen, L. B., Lenjisa, J. L., Yu, M., Brown, M. P., & Wang, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0076 · Cited by 17
Zhao, H., Hu, X., Cao, K., Zhang, Y., Zhao, K., Tang, C., & Feng, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.043 · Cited by 17
Metadata
- Authors
- Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., Brodfuehrer, J., Choi, C., Barvian, M. R., & Fry, D. W.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Toogood, Peter L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-02
- Volume
- 48
- Issue
- 7
- Pages
- 2388-2406
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1985389450
- Cited by
- 513
- References
- 50
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 20 · 2023: 25 · 2022: 38 · 2021: 32 · 2020: 32 · 2019: 30 · 2018: 44 · 2017: 42 · 2016: 34 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6, CDK4/6 inhibitors, kinase selectivity, G1 cell cycle arrest, palbociclib, small-molecule kinase inhibitors, anticancer drug candidates, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Biological Availability, Humans, Male, Piperazines, Proto-Oncogene Proteins, Pyridines, Pyrimidines, Structure-Activity Relationship, Thymidine, G1 Phase, Rats, Sprague-Dawley, Cyclin-Dependent Kinases, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.